Statement on the maximum residue level for propamocarb in lettuces
TL;DR
The paper sets a safe maximum residue level for propamocarb in lettuces to protect consumer health.
Contribution
It identifies a new fall-back MRL of 30 mg/kg for propamocarb in lettuces.
Findings
An MRL of 30 mg/kg is safe for propamocarb in lettuces.
Short-term and long-term intake from this MRL is unlikely to harm consumers.
Residue data from several Member States supported the new MRL.
Abstract
In accordance with Article 43 of Regulation (EC) No 396/2005, EFSA received a mandate from the European Commission to provide a statement on the maximum residue level (MRL) of propamocarb in lettuces. EFSA was mandated to identify a safe fall‐back MRL in lettuces since, for the current MRL of 40 mg/kg, acute consumer intake concerns could not be excluded. After an ad hoc data call, some Member States reported several potential fall‐back good agricultural practices (GAPs) and submitted residue trial data to support the fall‐back MRL options. An appropriate fall‐back MRL value of 30 mg/kg was identified by EFSA. EFSA concluded that the short‐term and long‐term intake of residues of propamocarb in lettuces (resulting from the fall‐back GAPs considered in the present statement) and of residues in other commodities of food and animal origin is unlikely to present a risk to consumer health.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAgricultural safety and regulations · Pesticide Residue Analysis and Safety · Pharmaceutical Economics and Policy